1-(2-溴乙氧基)-2-氯苯 | 18800-26-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-溴乙氧基)-2-氯苯
• 英文名称: 1-(2-bromoethoxy)-2-chlorobenzene
• 英文别名: 2-(2-Chlor-phenoxy)-ethylbromid
• CAS: 18800-26-5
• 化学式: C₈H₈BrClO
• mdl: MFCD02030661
• 分子量: 235.508
• InChiKey: ZDEJJQHQIOWTPC-UHFFFAOYSA-N

物化性质

• 熔点：
  10-11 °C
• 沸点：
  140-142 °C (15 mmHg)
• 密度：
  1.518±0.06 g/cm3(Predicted)
• 闪点：
  150 °C
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 储存条件：
  存于阴凉干燥处。

SDS

Name:	1-(2-Bromoethoxy)-2-chlorobenzene Material Safety Data Sheet
Synonym:
CAS:	18800-26-5

Section 1 - Chemical Product MSDS Name:1-(2-Bromoethoxy)-2-chlorobenzene Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18800-26-5	1-(2-Bromoethoxy)-2-chlorobenzene		unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18800-26-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 140 - 142 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: 150 deg C ( 302.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >150 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8BrClO
Molecular Weight: 235.51

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18800-26-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Bromoethoxy)-2-chlorobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 18800-26-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18800-26-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18800-26-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙氧基)-2-氯苯 在 乙醚 、 sodium 作用下， 生成 2,3-二氢苯并呋喃
  参考文献：
  名称：

  Stoermer; Goehl, Chemische Berichte, 1903, vol. 36, p. 2875 Anm. 2

  摘要：

  DOI：
• 作为产物：
  描述：

  邻氯苯酚 、 1,2-二溴乙烷 在 四丁基溴化铵 、 sodium hydroxide 作用下， 生成 1-(2-溴乙氧基)-2-氯苯
  参考文献：
  名称：

  喹啉-1H-1,2,3-三唑分子杂化物的合成、抗菌评估和计算机研究。

  摘要：

  摘要 抗菌素耐药性已成为对全球公共卫生的重大威胁，因此迫切需要具有改善治疗效果的新药。在这方面，分子杂交被认为是提供多靶点候选药物的可行策略。在此，我们报告了通过铜 (I) 催化的叠氮化物-炔烃 [3 + 2] 偶极环加成反应 (CuAAC) 合成的喹啉—1 H -1,2,3-三唑分子杂化物库。抗菌评估确定化合物16是文库中最活跃的杂合体，对耐甲氧西林金黄色葡萄球菌、大肠杆菌、鲍曼不动杆菌的 MIC 80值为 75.39 μM，具有广谱抗菌活性。和多重耐药肺炎克雷伯菌。该化合物还显示出有趣的抗白色念珠菌和新型念珠菌的抗真菌特性，MIC 80值分别为 37.69 和 2.36 μM，优于氟康唑。体外毒性分析显示对人红细胞 (hRBC) 无溶血活性，但对人胚胎肾细胞 (HEK293) 有部分细胞毒性。此外，计算机研究预测了优异的药物样特性以及三唑环在稳定与靶蛋白络合方面的重要性。总体而言，这些

  DOI：

  10.1007/s11030-020-10112-3
• 作为试剂：
  描述：

  邻氯苯酚 、 1,2-二溴乙烷 、 sodium hydroxide 在 氯仿 、 氯化钠 、 magnesium sulfate 、 silica gel 、 1-(2-溴乙氧基)-2-氯苯 作用下， 生成 1-(2-溴乙氧基)-2-氯苯
  参考文献：
  名称：

  Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain

  摘要：

  某些1,4-二氢吡啶化合物，可用作肾上腺素能阻滞剂和钙通道阻滞剂，化合物的化学式如下：其中，R1为氢、卤素、C1-6烷基或C1-6烷氧基，R3为氢、卤素、C1-6烷基、C1-6烷氧基或CF3(CH2)nO-，其中n为1、2或3，R5为-NHCH2CH2O-或-N(CH2CH2)2N-。

  公开号：

  US06846826B2

文献信息

• Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)
  作者：Xiaoke Guo、Xianglei Ma、Qian Yang、Jing Xu、Lu Huang、Jianmin Jia、Jiaojiao Shan、Li Liu、Weilin Chen、Hongxi Chu、Jinlian Wei、Xiaojin Zhang、Haopeng Sun、Yiqun Tang、Qidong You

  DOI：10.1016/j.ejmech.2014.03.075

  日期：2014.6

  and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。
• Synthesis of New 1,4-Diarylimidazoles and 1-Aryl-4-(5-Nitrofuran-2-il)imidazoles and Study of Their Anti-Infective Activity
  作者：T. A. Kuzmenko、L. N. Divaeva、A. S. Morkovnik、Yu. V. Koshchienko、A. A. Zubenko、Yu. D. Drobin、L. N. Fetisov、A. N. Bodryakov

  DOI：10.1134/s1068162018050096

  日期：2018.11

  1-R-3-acylmethylbenzimidazolium salts have been obtained which transformed under the action of ammonium acetate into the previously undescribed 1,4-diarylimidazoles and 1-aryl-4- (5-nitrofuran-2-il)imidazoles. The antiprotozoal, fungistatic, and antimicrobial activities of these compounds have been tested.

  使用 1-R-苯并咪唑和 ω-溴苯乙酮或 2-溴乙酰-5-硝基呋喃，已获得相应的 1-R-3-酰基甲基苯并咪唑季盐，其在乙酸铵的作用下转化为先前未描述的 1,4-二芳基咪唑和 1-芳基-4-(5-硝基呋喃-2-il)咪唑。已经测试了这些化合物的抗原生动物、抑真菌和抗微生物活性。
• [EN] CARBIDOPA PRODRUGS AND USES THEREOF<br/>[FR] PROMEDICAMEMTS DE CARBIDOPA ET LEURS UTILISATIONS
  申请人：XENOPORT INC

  公开号：WO2004052841A1

  公开（公告）日：2004-06-24

  Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.

  卡比多巴的前药、卡比多巴前药的衍生物、卡比多巴及其衍生物前药的制作方法、卡比多巴及其衍生物前药的使用方法以及卡比多巴及其衍生物前药的组合物被公开。
• Substituted azepino[4,5b] indoline derivatives
  申请人：——

  公开号：US20020077318A1

  公开（公告）日：2002-06-20

  The invention provides compounds of Formula (I): 1 wherein R 1 -R 4 , p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.

  该发明提供了Formula (I)的化合物： 其中R1-R4，p和q的取值如规范中描述的任何值，以及其药用盐，以及含有这种化合物或盐的药用组合物。这些化合物和盐是5-HT配体，对于治疗哺乳动物中涉及5-HT受体活性的疾病、紊乱和/或症状是有用的。这些化合物和盐特别适用于治疗中枢神经系统疾病。
• 3-Azabicyclo&lsqb;3.1.0&rsqb;hexane derivatives useful in therapy
  申请人：Pfizer INC

  公开号：US06313312B1

  公开（公告）日：2001-11-06

  Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.

  化合物的结构式（I），其盐及其前药，其中取代基如本文所定义，被披露为在治疗鸦片类物质介导的疾病中有用的鸦片受体结合剂。还描述了制备这类物质的方法。